Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival

Executive Summary

Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.

You may also be interested in...



FDA's Promotional Reviews Decline, But Says It's Only Part Of Job

US agency's Office of Prescription Drug Promotion may complete 37% fewer drug promotional material reviews in FY 2017 than previous year.

Woodcock Wants Rapid Regulatory Policy Development

CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.

Woodcock Wants Rapid Regulatory Policy Development

CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.

Related Content

Topics

UsernamePublicRestriction

Register

PS119881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel